Jefferies Starts Cue Biopharma (CUE) at Buy, 'Following Nature's "Cues" W/ Targeted IL-2 Therapy'

(Updated - March 13, 2024 4:08 AM EDT)

Jefferies analyst Maury Raycroft initiates coverage on Cue Biopharma (NASDAQ: CUE) with a Buy rating and a price target of $6.00.

The analyst comments "Novel IL-2 platform aims to improve on 1st-gen IL-2 safety/efficacy. Lead CUE-101 has shown early but promising mono & +pembro data in HPV+ HNSCC w/ regulatory alignment from EOP1 on paths fwd. Co also has CUE-102 (tgts WT-1; same platform) in ph.I & add'l upside w/ intriguing autoimmune pipeline. We think platform is interesting w/ HNSCC oppty undervalued. Partnership this yr could alleviate cash overhang & catalyze stock. Initiate Buy."

For an analyst ratings summary and ratings history on Cue Biopharma click here. For more ratings news on Cue Biopharma click here.

Shares of Cue Biopharma closed at $1.77 yesterday.

You May Also Be Interested In

• Jefferies Starts Aehr Test Systems (AEHR) at Buy
• BMO Capital Starts Energy Fuels (UUUU) at Outperform
• Kotak Upgrades Honasa Consumer Ltd (HONASA:IN) to Buy (1)